Drugs / Grass-SPIRE
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02161107 | Apr 2014 → Mar 2015 | asthma, seasonal allergic rhinitis | Circassia Limited | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02795273 | May 2016 → Oct 2018 | conjunctivitis, rhinitis | Circassia Limited | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2014-11-11 | Niox | Results Circassia Interim Management Statement niox.com ↗
Results show continued reduction in Total Rhinoconjunctivitis Symptom Score (TRSS) vs placebo after three seasons in two treatment groups (8 x 6 nmol and 4 x 12 nmol) despite no further doses |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-11-11 | Niox | Circassia Interim Management Statement niox.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Grass-SPIRE | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02795273 ↗ |
| Route | Other | “Eight intradermal injections of Grass-SPIRE” NCT02795273 ↗ |